Nanjing Medlander Medical Technology Co (SHSE:688273) Current Deferred Revenue: ¥43.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688273 Nanjing Medlander Medical Technology Co Ltd SHSE:688273
81 GF Score
Price ¥30.41
GF Value ¥35.19
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Nanjing Medlander Medical Technology Co Current Deferred Revenue?

Nanjing Medlander Medical Technology Co SHSE:688273 +3.08% 81 Current Deferred Revenue is ¥43.9 Mil as of Jun. 2026. GuruFocus rates SHSE:688273 with a GF Score™ of 81/100 and a GF Value™ of ¥35.19 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Nanjing Medlander Medical Technology Co's current deferred revenue for the quarter that ended in Jun. 2026 was ¥43.9 Mil.

Nanjing Medlander Medical Technology Co Current Deferred Revenue Related Terms

Nanjing Medlander Medical Technology Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Nanjing Medlander Medical Technology Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Medlander Medical Technology Co Current Deferred Revenue Chart

Nanjing Medlander Medical Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 33.30 47.98 45.66 51.27 51.61

Nanjing Medlander Medical Technology Co Quarterly Data
Mar21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.29 27.09 51.61 40.71 43.89
SHSE:688273
81GF Score
Nanjing Medlander Medical Technology Co Ltd SHSE:688273
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ¥43.9 Mil mean?
Nanjing Medlander Medical Technology Co (SHSE:688273) has a Current Deferred Revenue of ¥43.9 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Nanjing Medlander Medical Technology Co and its competitors.
Is Nanjing Medlander Medical Technology Co's Current Deferred Revenue too high?
Nanjing Medlander Medical Technology Co's current Current Deferred Revenue is ¥43.9 Mil. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's Current Deferred Revenue compare to ABT and SYK?
Nanjing Medlander Medical Technology Co's Current Deferred Revenue of ¥43.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Nanjing Medlander Medical Technology Co and its competitors. Nanjing Medlander Medical Technology Co's current Current Deferred Revenue is ¥43.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥35.19, compared to a current price of ¥30.41 — trading 13.6% below its estimated fair value. The current Current Deferred Revenue is ¥43.9 Mil. Nanjing Medlander Medical Technology Co's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current Current Deferred Revenue is ¥43.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be undervalued. The current stock price of ¥30.41 is trading 13.6% below its estimated GF Value™ of ¥35.19. GuruFocus considers Nanjing Medlander Medical Technology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688273:

  • Current Deferred Revenue: ¥43.9 Mil
  • GF Value™: ¥35.19 vs. price of ¥30.41 (13.6% below fair value)
  • GF Score™: 81/100 with 9 warning signs

No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing Medlander Medical Technology Co Business Description

Address Fengzhan Road, No. 32, Building A2, Yuhuatai District, Jiangsu Province, Nanjing, CHN, 210012
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
81GF Score

Get the complete analysis for SHSE:688273

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥30.41
Price
¥35.19
GF Value